Dogwood Therapeutics, Inc. (DWTX) stock
DWTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.08+0.02 (+1.89%)
Close on Nov 17, 2026Market cap $36.71MP/E –Yield –
Dogwood Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Dogwood Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $22.78M, up 189.8% year over year. For fiscal 2025 it was $21.87M, up 519.3% from the year before. The highest annual figure on record is $21.87M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.87M | +519.3% |
| FY2024 | Dec 31, 2024 | $3.53M | +104.3% |
| FY2023 | Dec 31, 2023 | $1.73M | -78.6% |
| FY2022 | Dec 31, 2022 | $8.07M | -25.3% |
| FY2021 | Dec 31, 2021 | $10.80M | +5464.4% |
| FY2020 | Dec 31, 2020 | $194.01K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.25M | +26.3% |
| Q1 FY2026 | Mar 31, 2026 | $2.67M | +9.6% |
| Q4 FY2025 | Dec 31, 2025 | $2.34M | +0.9% |
| Q3 FY2025 | Sep 30, 2025 | $14.52M | +2613.4% |
| Q2 FY2025 | Jun 30, 2025 | $2.57M | +664.7% |
| Q1 FY2025 | Mar 31, 2025 | $2.44M | +609.0% |
| Q4 FY2024 | Dec 31, 2024 | $2.32M | +676.3% |
| Q3 FY2024 | Sep 30, 2024 | $535.16K | +43.0% |
| Q2 FY2024 | Jun 30, 2024 | $336.08K | -39.8% |
| Q1 FY2024 | Mar 31, 2024 | $343.72K | -30.9% |
| Q4 FY2023 | Dec 31, 2023 | $298.32K | -76.5% |
| Q3 FY2023 | Sep 30, 2023 | $374.20K | -76.9% |
| Q2 FY2023 | Jun 30, 2023 | $557.84K | -76.8% |
| Q1 FY2023 | Mar 31, 2023 | $497.71K | -82.0% |
| Q4 FY2022 | Dec 31, 2022 | $1.27M | -56.4% |
| Q3 FY2022 | Sep 30, 2022 | $1.62M | -45.2% |
| Q2 FY2022 | Jun 30, 2022 | $2.41M | -25.0% |
| Q1 FY2022 | Mar 31, 2022 | $2.77M | +62.2% |
| Q4 FY2021 | Dec 31, 2021 | $2.92M | +9000.4% |
| Q3 FY2021 | Sep 30, 2021 | $2.96M | +2639.6% |
| Q2 FY2021 | Jun 30, 2021 | $3.21M | +13661.6% |
| Q1 FY2021 | Mar 31, 2021 | $1.71M | +5489.4% |
| Q4 FY2020 | Dec 31, 2020 | $32.07K | – |
| Q3 FY2020 | Sep 30, 2020 | $108.09K | – |
| Q2 FY2020 | Jun 30, 2020 | $23.32K | – |
| Q1 FY2020 | Mar 31, 2020 | $30.54K | – |
See a number that looks wrong?